Our in vivo animal studies on CT26 syngenic and HT29 xenograft mouse models showed that the anti-tumor effect of SMA was dose-dependent and close to effect generated by 5-FU, which is the most commonly used cytotoxic anti-cancer drugs. This evidence concerns the gene SMN1 and neoplasm.